The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).
 
Sandra Aung
Employment - Prometheus
Leadership - Prometheus
Patents, Royalties, Other Intellectual Property - UbiVac; UbiVac (I)
 
Michael A. Morse
Stock and Other Ownership Interests - Phytochem
Honoraria - Amgen; Bayer/Onyx; Bristol-Myers Squibb; Genentech/Roche; Lexicon; Novartis; Prometheus; Sanofi
Consulting or Advisory Role - Bayer/Onyx; Genentech/Roche
Speakers' Bureau - Genentech; Prometheus
Research Funding - Aduro Biotech; Advanced Accelerator Applications; AlphaVax; Lexicon; Onyx; Prometheus
 
Michael K.K. Wong
No Relationships to Disclose
 
Howard Kaufman
Consulting or Advisory Role - Alkermes; Amgen; Merck; Merck Serono; Prometheus
Research Funding - Bristol-Myers Squibb/Medarex
 
Gregory A. Daniels
No Relationships to Disclose
 
David F. McDermott
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer
Research Funding - Prometheus